AstraZeneca and IDT Biologika sign letter of intent to increase COVID-19 vaccine manufacturing in Europe and secure long-term supply capacity

Following the European Medicines Agency (EMA) approval, millions of AstraZeneca vaccines began shipping on 5 February as part of the initial 17m doses that are due to be delivered over the next weeks, with more planned in March. AstraZeneca and IDT Biologika are exploring options to accelerate output of finished COVID-19 Vaccine AstraZeneca in the second quarter of 2021 in order to help support Europe's immediate vaccination needs during the pandemic.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news